Home
overview
During the last decade major progress has been made in understanding neurodegenerative diseases, both at clinical and scientific levels. Advances in understanding pathophysiologic mechanisms have resulted in a wide array of novel treatment approaches. There is now a real potential to develop therapies which will slow and possibly stop many of these conditions. With a ‘greying’ population, there is a huge potential market and the need for new therapies is growing.

Our second Neurodegenerative Disorders event promises to be as successful as the first and will address the very latest advances in neurodegenerative disorders. This event will cover therapeutic developments in areas such as Parkinson's and Alzheimer's which are two of the biggest disorders in the market. The conference will also cover genetic aspects, amyloids, target identification, ion channels and other novel therapies of neurodegenerative disorders. Economic, regulatory and legal issues of prime importance to the industry will also be discussed. The conference aims to bring together leaders in the fields of neurological disorders and drug development to offer an insight into developments in neurodegenerative disorders and to analyse future directions for this important industry.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Malcolm Sheardown

Dr Malcolm Sheardown, Distinguished Research Fellow, Vernalis

9:10 AGEING

Dr Gavin Kilpatrick

Dr Gavin Kilpatrick, Research Director, CeNeS

  • The ageing population
  • Age-related diseases
  • Degenerative diseases of the brain
  • New opportunities for preventing and treating disease
  • Novel therapeutic agents
  • Future advances
  • 9:40 ALZHEIMER’S DISEASE

    Dr Hans Basun

    Dr Hans Basun, Senior Clinical Research Physician, AstraZeneca

  • Causes of AD
  • Diagnostic measures
  • How is AD treated?
  • Novel therapeutics
  • Overcoming challenges
  • Future opportunities
  • 10:20 PARKINSON’S DISEASE

    Dr Jim Murray

    Dr Jim Murray, Chief Executive Officer, Hunter-Fleming

  • Background
  • Clinical manifestations
  • Pathology
  • Present treatments
  • New therapies
  • Summary
  • 11:00 Morning Coffee

    11:20 NEURODEGENERATION IN MULTIPLE SCLEROSIS

    Dr David Baker

    Dr David Baker, Senior Lecturer, Institute of Neurology, University College London

  • MS as a neurodegenerative disease
  • Models of inflammatory neurodegeneration
  • Symptoms and management
  • Cannabinoids in treatment
  • 12:00 THE THREE R’S OF STROKE THERAPY

    Dr Adrian Carter

    Dr Adrian Carter, CD Corporate Development, Boehringer Ingelheim

  • Modern thrombolytic therapy
  • Doom and gloom for neuroprotection
  • Learning from experience
  • Novel rescue strategies
  • White matter is important, too
  • Future advances in regenerative medicine
  • 12:40 Lunch

    13:40 MILD COGNITIVE IMPAIRMENT (MCI)

    Prof. Giulio Pasinetti

    Prof. Giulio Pasinetti, Professor, Department of Psychiatry, Mount Sinai School of Medicine

  • MCI: Clinical characterisation and outcome
  • Microarray studies
  • The role of amyloids in MCI
  • Molecular characterisation of genes in animal models
  • Therapeutic intervention
  • Effective therapies
  • 14:20 ACUTE AND CHRONIC NEURODEGENERATIVE DISEASE

    Dr Alan Foster

    Dr Alan Foster, Senior Director, Neuroscience, Neurocrine Biosciences

  • Mechanisms in amyotrophic lateral sclerosis (ALS)
  • Mechanisms in stroke
  • Treatments based on glutamate transport
  • Treatments based on CRF
  • Future therapies
  • 15:00 ALZHEIMER’S DISEASE THERAPEUTICS

    Dr Huw Lewis

    Dr Huw Lewis, Senior Research Biologist, Merck Sharp & Dohme

  • The dependence of y-secretase activity on presenilins
  • Characteristics of the y-secretase complex
  • A novel mechanistic paradigm: regulated intramembrane proteolysis
  • Substrate specificity – APP & Notch
  • 15:40 Afternoon Tea

    16:00 NEUROPROTECTION: A STRATEGY FOR NEURODEGENERATIVE DISEASES INCLUDING HUNTINGDON’S DISEASE AND ALZHEIMER’S DISEASE

    Dr Vincent Simmon

    Dr Vincent Simmon, President & Chief Executive Officer, Cortex Pharmaceuticals

  • Neuroprotection by AMPA receptor modulation
  • Pathology of Alzheimer’s disease
  • Pathology of Huntingdon’s disease
  • Neuroprotection in Huntingdon’s disease
  • Future opportunities
  • 16:40 NEURODEGENERATIVE DISEASE

    Dr Donna Barten

    Dr Donna Barten, Senior Research Investigator, Neuroscience Drug Discovery, Bristol-Myers Squibb

  • Features of neurodegenerative disease
  • Models of ALS
  • Models of Alzheimer’s disease
  • Other models of dementia
  • The use of models in drug discovery
  • 17:20 PEP:TRANS

    Dr Luc-Andre Granier

    Dr Luc-Andre Granier, Vice President, Medical Director, Synt:em

  • Drug delivery to the CNS: a brief overview
  • Pep:trans approach: effective solution for brain delivery
  • Mechanism of action
  • PK studies after systemic administration
  • Application in CNS diseases
  • 18:00 Chairman's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Prof. Giulio Pasinetti

    Prof. Giulio Pasinetti, Professor, Department of Psychiatry, Mount Sinai School of Medicine

    9:10 TARGET IDENTIFICATION

    Dr Martin Citron

    Dr Martin Citron, Associate Director Research, Amgen

  • Alzheimer’s and Parkinson’s disease – mechanistic hypotheses
  • Pros and cons of disease mechanism based approaches
  • Developing screens to discover potential drug candidates
  • Successes and failures
  • Future opportunities
  • 9:40 NEW TARGETS FOR NEURODEGENERATION

    Dr Sarah Harper

    Dr Sarah Harper, Research Fellow, Merck Sharp & Dohme

  • The cell death pathways
  • Expression of MAP kinases in models of neurodegeneration
  • P38 & JNK family
  • ERK family
  • Effects of MAP kinase inhibitors in animal models of neurodegeneration
  • Potential new therapies for AD, PD and stroke?
  • 10:20 DISCOVERY AND VALIDATION OF NOVEL DRUG TARGETS IN NEURODEGENERATIVE DISEASES

    Dr Roman Urfer

    Dr Roman Urfer, Vice President, Drug Discovery & Development, AGY Therapeutics

  • Analysis of animal disease models for Stroke and Alzheimer’s disease
  • Gene expression analysis and target discovery using high-density cDNA arrays
  • Elucidation of signalling pathways of the disease process through mining of tome-course gene expression data and gene sequence databases
  • High-throughput validation of targets using multiple functional methods, including our proprietary RNAi technology
  • Assay development for validated targets and high-throughput screening of compound libraries
  • 11:00 Morning Coffee

    11:20 NEUROTROPHINS AND NEURODEGENERATIVE DISORDERS

    Dr Jean-Marie Grumel, MD

    Dr Jean-Marie Grumel, MD, Head od Development Programme, NeuroTell AG

  • Relationship between neurotrophins and neurodegenerative disorders
  • Interactions between neurotrophins and the cholinergic system
  • NeuroTell's Drug Discovery Platform
  • Effects of NeuroTell's lead compounds in animal models of neurodegeneration
  • 12:00 PROTEOMIC SCREENING OF NEURODEGENERATIVE DISEASES

    Dr Huw Davies

    Dr Huw Davies, UK Country Manager, Ciphergen Biosystems

  • Introduction to system and methodology
  • Protein biomarker discovery and validation
  • Interfacing with pattern recognition software for applications in predictive medicine
  • Strategies for protein ID
  • Monitoring multiple beta amyloid peptide variants using a single immunoassay
  • 12:40 Lunch

    13:40 ALZHEIMER’S PATHOLOGY IN A TRANSGENIC MOUSE MODEL

    Dr Patrick May

    Dr Patrick May, Head, Neuroscience Discovery Research, Eli Lilly

  • The implication of the beta amyloid peptide (Aß) as causative in Alzheimer's disease (AD)
  • How is the Aß peptide formed
  • Reducing Aß production by functionally inhibiting g-secretase both in cell and animal models of AD.
  • The in vivo and in vitro effects of these molecules
  • The potential usefulness of these molecules in the treatment of AD
  • 14:20 TRANSGENIC MOUSE MODELS FOR ALZHEIMER’S DISEASE

    Prof. Fred Van Leuven

    Prof. Fred Van Leuven, Professor, Head, Experimental Genetics Group, K. U. Leuven

  • Amyloid
  • Target identification
  • Calcium homeostasis
  • Passive and active immunization
  • Potential aspects in therapy
  • Related neurodegenerative disorders
  • 15:00 ANIMAL MODELS FOR CHRONIC NEURODEGENERATIVE DISEASES

    Dr Rudolf Urbanics

    Dr Rudolf Urbanics, Deputy Director Research & Development, Biorex

  • Damage of mitochondrial electron transport is a common feature in neurodegenerative diseases
  • Pathological role of ROS generation of impaired mitochondria
  • Alzheimer’s disease – characterization of the azide model
  • Morphological, biochemical and behavioural changes in AD azide model
  • Parkinson’s disease – characterization of the rotenone model
  • Morphological, biochemical and behavioural changes in rotenone poisoning PD model

    Apoptosis in neurodegenerative diseases – neuroprotective therapy

  • 15:40 Afternoon Tea

    16:00 MEMORY ENHANCEMENT BY A NOVEL CLASS OF CALCIUM BINDING PROTEINS

    Prof. Patrick Nef

    Prof. Patrick Nef, Vice Director, Head of Psychiatry, F. Hoffman La-Roche

  • The role of NCS-1 in improving learning and memory using key animal models of cognition
  • 16:40 GENERATION OF KNOCK-OUT AND KNOCK-IN RATS

    Dr Alexandre Fraichard

    Dr Alexandre Fraichard, Chief Executive Officer & Chief Scientific Officer, GenOway

  • Quality of rat models in neuroscience
  • Gene targeting in rat
  • Deletion strategies: constitutive versus conditional KO
  • Humanisation of psychological pathways
  • Rat KO-Kin consortium
  • 17:20 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.